Not Tagged
Not Tagged
['mosunetuzumab', 'toci', 'lymsm']
time-limited mosunetuzumab monotherapy in r/r fl. pt up to age 90 (!!!) enrolled. orr 78% (cr 60%) with impressive dor, pfs, os not reached at 2 years. crs mostly gr1-2, grade 3+ aes were neutropenia and hypophos. impressive time-limited option in high-risk fl. #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????